[ad_1]
Acinois is a leader in more than 20 therapeutic areas, including gastroenterology, cardiovascular disease, and pain relief of high-quality pharmaceutical products in new forms of drug delivery. Acinois has its own sales team and distribution partnerships and is active in more than 90 countries. As a trusted partner of global pharmaceutical companies, Acino also provides customized one-stop solutions through contract manufacturing and outsourcing licenses.
Fahad Al Qassim, Executive Director of ADQ Healthcare and Pharmaceuticals commented: “On the basis of a series of strategic acquisitions throughout this year, we are creating a strong platform to consolidate the UAE’s position as a regional drug manufacturing, commercialization and distribution center in specific growth leading markets. Our health care for ADQ The goal of the pharmaceutical cluster is to ensure access to affordable essential medicines and to promote new and innovative treatments that help improve people’s lives. With the company’s industry experience and wide-ranging influence, Acino will enable ADQ to be available throughout the entire Achieve higher levels of growth, innovation and ambition in the pharmaceutical value chain.”
Acino CEO Steffen Saltofte said: “Acino is committed to promoting the development of healthcare by increasing access to high-quality medicines that patients and governments can trust and value, and ADQ’s support will accelerate this ambition. As a leading provider of advanced pharmaceutical solutions in emerging markets, we Having established a good reputation, we are excited about the business transformation and commercial growth potential of Acinojoin ADQ’s healthcare and pharmaceutical product portfolio.”
Build ADQ’s comprehensive pharmaceutical platform
Through the acquisition of Acino, ADQ intends to create a comprehensive pharmaceutical platform with formulation development, licensing, manufacturing and commercialization capabilities in selected growth-leading markets. Earlier this year, ADQ acquired amount Pharmaceutical Company, one of Egypt’s leading manufacturers, distributors and exporters of branded pharmaceuticals and animal health products, and Pharmax Pharmaceuticals, a UAE-based pharmaceutical company that produces and sells affordable brands Generic drugs. In addition, ADQ also purchased a minority stake in India-based Biocon Biologics Limited, which specializes in developing, manufacturing and selling high-quality, affordable biosimilars in the global market.
The final agreement is for ADQ to acquire 100% of Acino from its existing shareholders, including Nordic Capital and Avista Capital Partners. The transaction is subject to customary closing conditions, including regulatory approval.
[ad_2]
Source link